TAVR and the Risk of Thrombosis

Slides:

Advertisements

Similar presentations

PARTNER Objective To compare surgical aortic valve replacement (AVR) with transcatheter aortic valve replacement (TAVR) in high-risk patients with severe.

Advertisements

Heart Valve Thrombosis & Neuro-Outcomes

Addressing the Challenges in Primary and Secondary Stroke Prevention

Covering the Bases in Cardioversion

Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.

The Ever-Expanding Patient Pool for TAVR:

NOACs for Cancer-Associated Thrombosis:

Atrial Fibrillation and PCI

Anticoagulants in Interventional Cardiology:

NOACs In Long-term VTE Treatment: A State Of The Art Review

US Guidelines US Guidelines Low-risk Patients.

NOACs, AF, and PCI: What Do the Latest Data Suggest?

Achieving Long-Term Protection Post-MI

When Is Adding Aspirin to NOACs Worth the Risk?

Thrombosis, Cancer, and NOACs

The ABCs of AF.

Access to NOAC Therapy:

PAD Patients vs Post-ACS Patients:

A New Era for NOACs:.

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

Anticoagulation Highlights From the American Heart Association Meeting 2017.

Up to Date on Which NOAC for Which Patient

New Perspectives in AF and PCI: Implications for the Practicing Physician.

Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.

Antithrombotics and PAD: A New Paradigm in Practice

New Perspectives in CAD and PAD: Weighing the Latest Evidence

Oral Anticoagulants in AFa,b A Brief History.

Global Burden of VTE. Preventing Thrombosis During and Post-Hospitalization: New Paradigms in Clinical Care.

Selecting NOACs for High-Risk Patients

Revealing Characteristics of Patients at High Risk for Developing Atrial Fibrillation.

The Essentials for Secondary Stroke Prevention

Anticoagulation Therapy in Patients Post-TAVR

Assessing the Risk for Stroke in Patients With Atrial Fibrillation

Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:

Efficacy and Safety of Edoxaban in Patients With AF and HF

AF and PCI in Practice.

Access to NOAC Therapy:

PARTNER 2A Trial design: Intermediate-risk patients with aortic stenosis (STS PROM score 4-8%) were randomized to undergo either TAVR or SAVR, stratified.

Antithrombotic Protection in CAD and HF

How to Optimize TAVR Outcomes

Adherence in SPAF: Measures to Improve Care

What Anticoagulant Registries Are Revealing

Watching for the Patient With AF: Latest Advances and Technologies

Learning Objectives Classification of VTE Goals of VTE Treatment.

A Better Solution For Cancer Patients With VTE?

Real-World Evidence in VTE

Dos and Don’ts for High-Risk Elderly Patients With AF

Atrial Fibrillation.

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

Anticoagulation and Thrombosis Management

Aspirin and Cardioprevention in 2018

Assessing Atrial Fibrillation: Real-World Data vs Clinical Trials

Identifying High-Risk AF Patients

Factor Xa Inhibitors in PAD

Cancer-Associated Thrombosis

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

NOAC Studies in VTE AF Studies Superior Outcomes.

Program Goals Background: Anticoagulation in Patients With VTE.

The Challenge of AF and PCI: Practical Strategies to Improve Outcomes

Factor Xa Inhibitors in Coronary Artery Disease

The ABCs of AF.

5 Good Minutes on Atrial Fibrillation-related Stroke

What is “AF Burden”?. What is “AF Burden”? AF Burden and Stroke Risk ASSERT Study.

Antiarrhythmic Drugs in AF

Extraordinary Cases in Stroke Prevention

Antithrombotic Therapy in AF Patients Undergoing PCI

What's New in NOACs in AF?.

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Presentation transcript:

TAVR and the Risk of Thrombosis

Program Goals

Thromboembolic Risk Associated With TAVR

Timing of Stroke and Bleeding Post TAVR

Stroke After TAVR -- Pathophysiology

TAVR and AF Background

Leaflet Thrombosis in Bioprosthetic Aortic Valves: Clinical Outcomes

Current Indications for Antithrombotic Therapy After TAVR

DAPT vs SAPT in TAVR

ENVISAGE TAVI AF -- Study Design

NOAC SPAF Trials Meta-Analysis of 71,683 Patients

GALILEO: Study Design

Unanswered Questions in TAVR and the Potential Role for NOACs

Abbreviations

Abbreviations (cont)